Structures of new cancer drug candidates revealed

On March 20, the popular "First-Time Disclosures" session at ACS Spring 2024 offered a look behind the curtain of the drug development process with the unveiling of the structures of new clinical candidates. This year, it was cancer across the board as six companies—Oric Pharmaceuticals, Nurix Therapeutics, Schrödinger, Deciphera Pharmaceuticals, Tango Therapeutics, and Blueprint Medicines—presented structures and early clinical trial results for new oncology drug candidates in a hybrid session. But while all six candidates were connected in terms of the disease they're targeting, each one tells a different story about problem-solving in medicinal chemistry, said Nicole Goodwin of GSK, who organized and served as moderator for the first half of the session. Rachel Lagiakos of Schrödinger moderated the final three presentations; she'll be taking over the organizer role from Goodwin in future meetings. Candidate: ORIC-533 Presenter: Jared Moore, Oric Pharmaceuticals Target: CD73 Disease: Multiple myeloma In the first